Earnings and Guidance Put Doximity Stock in Focus

Doximity (DOCS) is in focus after first quarter earnings showed sales of US$156.62 million with lower net income of US$24.32 million, alongside updated revenue guidance for the second quarter and full fiscal year.

Doximity’s share price has climbed 27.31% over the past 90 days and 13.94% over the past month, yet remains down 43.36% year to date, while the 1 year total shareholder return is down 62.81%. This points to improving short term momentum following a weak longer term record as investors weigh stronger sales against softer profitability and the updated revenue guidance.

If you are assessing how this earnings reaction compares with other healthcare technology opportunities, it may be worth scanning 40 healthcare AI stocks

Doximity’s share price has already rebounded sharply while earnings power looks softer than a year ago. Do the current expectations and updated revenue outlook still leave enough upside for new buyers, or is most of the reward now priced in?

Most Popular Narrative: 27.2% Undervalued

Based on the most followed narrative, Doximity’s fair value of $33.70 sits well above the recent $24.52 close, which frames the stock as materially undervalued in that narrative.

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not a private practice.

According to Dc12, this valuation leans heavily on strong physician engagement, expectations for more effective monetization, and assumptions about steady margins and earnings from the healthcare software platform. The key question is how those usage patterns and profitability assumptions translate into long term cash flows and justify a fair value comfortably above today’s share price.

Result: Fair Value of $33.70 (UNDERVALUED)

However, stronger physician engagement will matter less if Doximity’s AI tools lose out to rivals or if monetization of that user base proves slower than hoped.

Next Steps

With mixed signals around Doximity’s recent performance and valuation story, it makes sense to move quickly and review the underlying details yourself. To see how the balance of potential risks and rewards stacks up before you decide what this earnings update means for you, take a closer look at the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Doximity?

If this Doximity update has sharpened your focus, do not stop here. Use the Simply Wall St Screener to uncover stocks that better fit your goals.

• Target potential upside by scanning companies that appear mispriced on fundamentals through the 53 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that feature robust payouts in the 10 dividend fortresses.
• Prioritize capital preservation and consistency by checking companies highlighted in the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.